An ounce of prevention is worth a pound of cure  by Blasi, F. & Mantero, M.
RE
A
M
I
d
b
a
a
p
p
a
m
o
w
t
y
t
r
f
9
e
i
a
r
t
a
f
t
r
v
n
m
t
t
f
f
h
i
0
hev Port Pneumol. 2014;20(2):60--61
www.revportpneumol.org
DITORIAL
n  ounce  of  prevention  is worth  a pound  of  cures
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3. Centers for Disease Control and Prevention (CDC). Estimatedais  vale  prevenir  do  que  remediar
nﬂuenza  and  pneumococcal  infections  are  major  causes  of
eath  and  disability  in  Europe,  mainly  affecting  children
etween  2  and  24  months  of  age  and  people  >65  years  of
ge.1,2
Despite  the  clear  effectiveness  of  the  vaccination
pproach,  it  has  to  be  one  of  the  major  achievements  of
ublic  health  for  population  protection,  both  the  general
opulation  and  health-care  workers  have  a  low  level  of
cceptance  of  vaccinations.3,4
Vaccination  programs  in  children  with  7-valent  pneu-
ococcal  conjugate  vaccine  have  reduced  the  incidence
f  invasive  pneumococcal  disease  (IPD)  by  almost  70%,
ith  the  herd  effect  in  adults  leading  to  an  18%  reduc-
ion  of  IPD  incidence  in  non-vaccinated  adults  aged  65
ears  or  more.5 Moreover,  the  use  of  such  vaccina-
ions  in  children  has  reduced  the  incidence  of  antibiotic
esistance,  according  to  records  for  1999  and  2002,
rom  40.8%  to  26.4%  for  penicillin,  from  34.9%  to
.4%  for  cephalosporin  and  from  29.5%  to  18.1%  for
rythromycin.6
The  introduction  of  10-  and  13-valent  vaccines,  increas-
ng  serotype  coverage,  may  expand  the  clinical  beneﬁts  in
dult  populations  at  risk  for  pneumococcal  disease.  The
esults  of  a  large  Dutch  randomized  controlled  trial  designed
o  test  the  efﬁcacy  and  effectiveness  of  13-valent  vaccine  in
dults  will  be  available  soon,  hopefully  supporting  indication
or  universal  vaccination.7
Epidemiological  evidence  indicates  that  inﬂuenza  con-
ributes  to  all-cause  mortality  and  to  cardiovascular  and
espiratory  hospitalisations  and  recent  studies  conﬁrm  that
accination  not  only  prevents  inﬂuenza  but  also  brings  sig-
iﬁcant  preventive  beneﬁts  for  patients  at  risk  for  acute
yocardial  infarction.8,9
The  Consensus  Document  for  the  prevention  of  respira-
ory  infections  in  adults,  published  in  this  issue,  underlines
he  importance  of  a  comprehensive  approach  to  prevention:
or  general  measures  and  vaccinations.10
Smoking,  high  alcohol  intake,  being  underweight,  suf-
ering  from  chronic  diseases,  living  in  a large  household  or
aving  regular  contact  with  children  are  associated  with  an
ncreased  risk  of  pneumonia.11
873-2159/$  –  see  front  matter  ©  2014  Sociedade  Portuguesa  de  Pneumolo
ttp://dx.doi.org/10.1016/j.rppneu.2014.02.002Smoking  cessation  (and  prevention)  is  clearly  a  major
tep  towards  reducing  the  burden  of  respiratory  infections
ncluding  tuberculosis  and  deserves  comprehensive  tobacco-
ontrol  strategies  including  strong  public  campaigns  as
ndicated  by  WHO  and  by  ATS  and  ERS.12,13
On  the  other  hand,  better  management  of  chronic  dis-
ases  is  a  cornerstone  of  prevention  of  respiratory  infections
nd  vaccinations  are  a  cornerstone  of  the  best  management
f  these  diseases.
Vaccination  strategies  based  on  the  use  of  more  effective
accines  are  expected  to  have  a  substantial  public  health
mpact  on  respiratory  infections  and  health  services  costs  by
educing  the  burden  of  inﬂuenza  and  pneumococcal  infec-
ions.
Another  important  issue  that  should  be  taken  into
ccount  when  considering  prevention  of  respiratory  infec-
ions  is  the  role  of  health  disparities.
Lower  socioeconomic  status  and  belonging  to  ethnic
inorities  are  associated  with  higher  prevalence  of  tobacco
moking,  environmental  exposures,  occupational  hazards,
oor  nutrition  and  lack  of  access  to  quality  healthcare
ncluding  vaccinations.13
As  stated  in  the  consensus  document,  a  comprehensive
pproach  to  prevention  and  a  proactive  policy  to  implemen-
ing  the  recommendations  are  mandatory  and  of  paramount
mportance  in  reducing  the  present  and  future  burden  of
espiratory  infections.
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